CURX

Curanex Pharmaceuticals Inc Common Stock

CURX

Market cap $144M

5.19 USD

+0.53

11.37%

At close Updated Aug 28, 4:00 PM EDT

Pre-market

After hours

5.21

+0.02

0.39%

1 day

11.37%

5 days

36.58%

1 month

29.1%

3 months

29.1%

6 months

29.1%

Year to date

29.1%

1 year

29.1%

5 years

29.1%

10 years

29.1%

About: Curanex Pharmaceuticals Inc is engaged in discovering, developing, and commercializing botanical drugs for treating unmet medical needs in patients with inflammatory disease. Its compound, Phyto-N, is in preclinical research for six indications: ulcerative colitis, atopic dermatitis, COVID-19, type 2 diabetes, nonalcoholic fatty liver disease (NAFLD) and gout.

Healthcare Drug Manufacturers - General

–

Funds holding %

of 7,444 funds

–

Analysts bullish %

Financial journalist opinion

Curanex Pharmaceuticals Inc. Announces Closing of its Initial Public Offering

Jericho, New York, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Curanex Pharmaceuticals Inc. (Nasdaq: CURX) ("Curanex" or the "Company"), a developmental stage pharmaceutical company focused on discovering and developing botanical drugs for inflammatory diseases, today announced the closing of its initial public offering (the “Offering”) of 3,750,000 shares of common stock at a public offering price of $4.00 per share, for gross proceeds of $15 million, before deducting underwriting discounts and offering expenses. The Offering was conducted on a firm commitment basis. The Company's shares of common stock began trading on the Nasdaq Capital Market on August 26, 2025 under the ticker symbol "CURX."

Curanex Pharmaceuticals Inc. Announces Closing of its Initial Public Offering

Curanex Pharmaceuticals Inc. Announces Pricing of its Initial Public Offering

Jericho, New York, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Curanex Pharmaceuticals Inc. (Nasdaq: CURX) ("Curanex" or the "Company"), a developmental stage pharmaceutical company focused on discovering and developing botanical drugs for inflammatory diseases, today announced the pricing of its initial public offering (the “Offering”) of 3,750,000 shares of common stock at a public offering price of $4.00 per share, for gross proceeds of $15 million, before deducting underwriting discounts and offering expenses. The Offering is being conducted on a firm commitment basis. The Company's shares of common stock are expected to begin trading on the Nasdaq Capital Market on August 26, 2025, under the ticker symbol "CURX."

Curanex Pharmaceuticals Inc. Announces Pricing of its Initial Public Offering

See News Rankings

Charts implemented using Lightweight Charts™